CMS-PDX: A 20-gene genomic panel to predict consensus molecular subtypes in patient-derived xenografts (PDX) of colorectal cancer.

被引：0
|
作者：
Buechler, Steven Allen
Gokmen-Polar, Yesim
Badve, Sunil S.
机构：
[1] Univ Notre Dame, Notre Dame, IN 46556 USA
[2] Indiana Univ Sch Med, Indianapolis, IN 46202 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 04期
关键词：
D O I：
10.1200/JCO.2019.37.4_suppl.598
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
598
引用
收藏
页数：1
相关论文
共 10 条
  • [1] Evaluation of potential predictive biomarker for cetuximab in a panel of colorectal cancer patient-derived xenografts (PDX)
    Rivera, M.
    Hoffmann, J.
    Wulf-Goldenberg, A.
    Schlag, P. M.
    Merk, J.
    Walther, W.
    Fichtner, I.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S54 - S55
  • [2] Establishment and characterization of early colorectal cancer patient-derived xenografts (PDX) as platform for drug screen, molecular- and biomarker analysis
    Rivera, M.
    Wulf-Goldenberg, A.
    Schlag, P. M.
    Kury, A.
    Merk, J.
    Hoffmann, J.
    Walther, W.
    Fichtner, I.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 74 - 74
  • [3] Patient-derived xenografts (PDX) identify JMJD6 inhibitor as an effective therapeutic medicine in colorectal cancer
    Ye, F.
    You, J.
    Xia, L.
    Lian, J.
    Xiao, R.
    Ran, T.
    Gao, X.
    Li, J.
    Zhao, X.
    Gao, J.
    Lin, H.
    Zheng, J.
    Liu, W.
    ANNALS OF ONCOLOGY, 2019, 30
  • [4] Novel Patient-Derived Xenografts (PDX) from Peritoneal Metastasis of Colorectal Cancer (PmCRC) for Improved Prediction of Therapy Response
    Dahlmann, Mathias
    Rau, Beate
    Brzezicha, Bernadette
    Buettner, Britta
    Pachmayr, Eva
    Popp, Oliver
    Mertins, Philipp
    Keilholz, Ulrich
    Walther, Wolfgang
    Stein, Ulrike
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 202 - 202
  • [5] Patient-derived xenografts (PDX) models of peritoneal metastasis from colorectal cancer to identify novel predictive biomarkers for improved therapy
    Pachmayr, E.
    Brzezicha, B.
    Buttner, B.
    Rau, B.
    Stein, U.
    Walther, W.
    CLINICAL & EXPERIMENTAL METASTASIS, 2019, 36 (02) : 147 - 147
  • [6] Antitumor activity of farletuzumab ecteribulin in a panel of endometrial cancer patient-derived xenografts with four different molecular subtypes
    Hasegawa, K.
    Yagishita, S.
    Shintani, D.
    Yoshida, H.
    Suzuki, M.
    Sato, S.
    Ogasawara, A.
    Nishikawa, T.
    Yonemori, K.
    Yasuda, M.
    Furuuchi, K.
    Uenaka, T.
    Hamada, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S529 - S529
  • [7] Novel patient-derived 3D (PD3D) cell models and matched patient-derived xenografts (PDX) from peritoneal metastasis of colorectal cancer for drug testing and biomarker analysis
    Regenbrecht, Christian R. A.
    Gambara, Guido
    Pachmayr, Eva
    Silvestri, Alessandra
    Dahlmann, Mathias
    Brzezicha, Bernadette
    Buettner, Britta
    Rau, Beate
    Keilholz, Ulrich
    Stein, Urike
    Walther, Wolfgang
    CANCER RESEARCH, 2018, 78 (13)
  • [8] Novel cancer gene variants and gene fusions of triple-negative breast cancers (TNBCs) reveal their molecular diversity conserved in the patient-derived xenograft (PDX) model
    Jung, Jaeyun
    Jang, Kiwon
    Ju, Jung Min
    Lee, Eunji
    Lee, Jong Won
    Kim, Hee Jung
    Kim, Jisun
    Lee, Sae Byul
    Ko, Beom Seok
    Son, Byung Ho
    Lee, Hee Jin
    Gong, Gyungyup
    Ahn, Sei Yeon
    Choi, Jung Kyoon
    Singh, Shree Ram
    Chang, Suhwan
    CANCER LETTERS, 2018, 428 : 127 - 138
  • [9] KRAS-mutant (mt) colorectal cancer (CRC) organoid models generated from patient-derived xenografts (PDX) show response to combination of trametinib (Tm), neratinib (N), and trastuzumab (Tz)
    Pal, Rekha
    Srinivasan, Ashok
    Lucas, Peter C.
    Allegra, Carmen J.
    Davies, Angela M.
    Lalani, Alshad S.
    Jacobs, Samuel A.
    Pogue-Geile, Katherine L.
    CANCER RESEARCH, 2019, 79 (13)
  • [10] Inflammatory and stem-like colorectal cancer (CRC) subtypes identified in patient-derived xenograft (PDX) models show tumor growth inhibition (TGI) by the combination of trametinib (T) and neratinib (N) irrespective of KRAS mutation (MT) status
    Pal, Rekha
    Song, Nan
    Wang, Ying
    Srinivasan, Ashok
    Lucas, Peter C.
    Allegra, Carmen J.
    Davies, Angela M.
    Lalani, Alshad S.
    Jacobs, Samuel A.
    Pogue-Geile, Katherine L.
    CANCER RESEARCH, 2018, 78 (13)
1